Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences

Real-time LB-102 target engagement using [11C]Raclopride PET

Andrei Molotkov, Mikhail Doubrovin, Martin Dolan, Simon Joseph, Andrew Vaino, Zachary Prensky and Akiva Mintz
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 79;
Andrei Molotkov
1Columbia University Medical Center New York NY United States
2Columbia University Medical Center New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikhail Doubrovin
1Columbia University Medical Center New York NY United States
2Columbia University Medical Center New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Dolan
1Columbia University Medical Center New York NY United States
2Columbia University Medical Center New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Joseph
1Columbia University Medical Center New York NY United States
2Columbia University Medical Center New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Vaino
3LB Pharmaceuticals New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary Prensky
3LB Pharmaceuticals New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akiva Mintz
1Columbia University Medical Center New York NY United States
2Columbia University Medical Center New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

This article has a correction. Please see:

  • Erratum - December 01, 2020

Abstract

79

Objectives: Schizophrenia is a debilitating disease affecting ~1% of the population. LB-102 is a novel benzamide selective D2/D3 agonist designed to improve blood brain barrier (BBB) permeability of amisulpride, a well-established dopamine antagonist used to treat schizophrenia in Europe. The objective of this study is to develop a translational method of non-invasively quantifying real-time target engagement by LB-102 that can be used in early phase clinical trials.

Methods: BALB/c mice (n=4) were administered LB-102 (100mg/kg) by oral gavage approximately 140 minutes prior to i.v. injection of [11C]Raclopride and subsequent microPET imaging. A control group (n=4) was scanned without prior blocking. Static Images were acquired 20-50 minutes post tracer injection on a Siemens Inveon microPET scanner and co-registered with a microCT (MILabs). Specific binding values were obtained by subtracting the cerebellar reference region in LB-102 treated and untreated mice. Data is presented as a percentage of [11C]Raclopride uptake blocked by LB-102 pretreatment.

Results: Significant reduction of [11C]Raclopride uptake in the striatum (68%) was achieved in the treated group following the administration of LB-102 compared to a robust striatal activity in the control untreated mice. [11C]Raclopride accumulation was specific to the striatal region without any significant uptake in other brain tissues (20:1 ratio to cerebellum in the control group).

Conclusions: [11C]Raclopride PET imaging of LB-102 D2 receptor binding is a translational method to quantitatively evaluate real-time target engagement of the D2 receptor that can be used in early phase dose finding studies as a companion to disease symptom endpoints. This is significant because quantitative PET imaging provides an objective means to assess drug actions that can add value to the more subjective clinical endpoints typically used in schizophrenia drug development. Support: Study was sponsored by LB Pharmaceuticals Inc. The PET early drug development program is supported by the Columbia Dept. of Radiology and Irving Institute CTSA Translational Therapeutics Accelerator (UL1TR001873).

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Real-time LB-102 target engagement using [11C]Raclopride PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Real-time LB-102 target engagement using [11C]Raclopride PET
Andrei Molotkov, Mikhail Doubrovin, Martin Dolan, Simon Joseph, Andrew Vaino, Zachary Prensky, Akiva Mintz
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 79;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Real-time LB-102 target engagement using [11C]Raclopride PET
Andrei Molotkov, Mikhail Doubrovin, Martin Dolan, Simon Joseph, Andrew Vaino, Zachary Prensky, Akiva Mintz
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 79;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • Erratum
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences

  • Multicenter trial study for usefulness of physical parameters toward the standardization of brain SPECT image: relation to visual analysis
  • Assessment of Brain Perfusion 123I-IMP SPECT imaging Using Low Energy High Resolution Collimator image reconstructed by Flash 3D
  • PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease
Show more Neurosciences

Basic Science - Synaptic activity and other mechanisms

  • Monitoring synaptic loss in a rat model of stroke: a PET imaging study with [18F]SynVesT-2, radiotracer for the synaptic vesicle protein 2A (SV2A)
  • NR2B
  • Single-cell analysis reveals the key role of enhanced endothelial glucose uptake in neurometabolic coupling
Show more Basic Science - Synaptic activity and other mechanisms

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire